PRS-300s

Candidate Targets Indication Partner Our Commercial
Rights
Discovery Preclinical IND-
enabling
Phase I Phase Ib/IIa
PRS-300s n.d. Immuno-Oncology Worldwide
Discovery Phase in progress
Pre-Clinical Phase not started
IND-enabling Phase not started
Phase 1 not started
Phase 2 not started

Targeting tumors through the powerful potential of Anticalin proteins. This approach may lead to improved efficacy over current tumor-targeted therapies and may avoid systemic side effects of monospecific immunomodulatory antibodies.

Novel approaches in immuno-oncology hold a lot of promise to help patients suffering from cancer. Within our PRS-300-Series, we are developing bi- and multispecific Anticalin fusion proteins against a variety of tumor and immunomodulatory targets. We thereby direct the immunomodulatory component to the tumor with the goal of selectively activating the immune system in the tumor microenvironment. This approach may lead to improved efficacy over current tumor-targeted therapies and may avoid systemic side effects of monospecific immunomodulatory antibodies.

We are actively pursuing multiple costimulatory and checkpoint targets, which can be combined with each other or with different tumor targets in multispecific drug candidates. For these multispecific compounds, we are testing different formats with different geometries. This allows us to test for an optimal synapse between T cells and tumor cells, and may lead to different pharmacodynamic effects of each molecule. Based on our ability to generate highly differentiated molecules with novel modes of action, we intend to make this area a core franchise of Pieris.